{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:13:31Z","timestamp":1790648011680,"version":"4.1.0"},"reference-count":248,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 81774050"],"award-info":[{"award-number":["NSFC 81774050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"crossref","award":["17JCJQJC46200"],"award-info":[{"award-number":["17JCJQJC46200"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin","doi-asserted-by":"crossref","award":["17JCYBJC29000"],"award-info":[{"award-number":["17JCYBJC29000"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"name":"State Key Development Program for Basic Research of China","award":["973 Program, No. 2012CB518404"],"award-info":[{"award-number":["973 Program, No. 2012CB518404"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10741-019-09807-z","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T07:19:12Z","timestamp":1560151152000},"page":"867-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Biomarkers in heart failure: the past, current and future"],"prefix":"10.1007","volume":"24","author":[{"given":"Michael","family":"Sarhene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch","family":"Acheampong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhengcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiaoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yunsheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Jingyuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Xiumei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Guanwei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"issue":"10","key":"9807_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ et al (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135(10):e146\u2013e603","journal-title":"Circulation"},{"issue":"14","key":"9807_CR2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787\u20131847","journal-title":"Eur Heart J"},{"issue":"9963","key":"9807_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators (2015) Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 385(9963):117\u2013171","journal-title":"Lancet"},{"issue":"1","key":"9807_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P et al (2014) Heart failure: preventing disease and death worldwide. Esc Heart Failure 1(1):4","journal-title":"Esc Heart Failure"},{"issue":"16","key":"9807_CR5","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW et al (2013) ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147\u2013e239","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"9807_CR6","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"6","key":"9807_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrcardio.2012.37","volume":"9","author":"T Ahmad","year":"2012","unstructured":"Ahmad T et al (2012) Novel biomarkers in chronic heart failure. Nat Rev Cardiol 9(6):347\u2013359","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"9807_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","unstructured":"Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89\u201395","journal-title":"Clin Pharmacol Ther"},{"issue":"19","key":"9807_CR9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1161\/CIRCULATIONAHA.104.482570","volume":"113","author":"RS Vasan","year":"2006","unstructured":"Vasan RS (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113(19):2335\u20132362","journal-title":"Circulation"},{"issue":"8","key":"9807_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nrcardio.2012.60","volume":"9","author":"AS Maisel","year":"2012","unstructured":"Maisel AS, Choudhary R (2012) Biomarkers in acute heart failure\u2014state of the art. Nat Rev Cardiol 9(8):478\u2013490","journal-title":"Nat Rev Cardiol"},{"key":"9807_CR11","unstructured":"Lindenfeld J et al (2010) HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 16(6):e1\u2013e194"},{"issue":"6","key":"9807_CR12","first-page":"776","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW et al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure. A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 70(6):776\u2013803","journal-title":"Circulation"},{"issue":"20","key":"9807_CR13","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1056\/NEJMra0800239","volume":"358","author":"E Braunwald","year":"2008","unstructured":"Braunwald E (2008) Biomarkers in heart failure. N Engl J Med 358(20):2148\u20132159","journal-title":"N Engl J Med"},{"issue":"17","key":"9807_CR14","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","volume":"119","author":"MA Hlatky","year":"2011","unstructured":"Hlatky MA et al (2011) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119(17):2408\u20132416","journal-title":"Circulation"},{"issue":"8","key":"9807_CR15","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1161\/CIRCULATIONAHA.106.683110","volume":"115","author":"DA Morrow","year":"2007","unstructured":"Morrow DA, Lemos JAD (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115(8):949\u2013952","journal-title":"Circulation"},{"issue":"1","key":"9807_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1373\/clinchem.2011.165720","volume":"58","author":"RR van Kimmenade","year":"2012","unstructured":"van Kimmenade RR, Januzzi JL Jr (2012) Emerging biomarkers in heart failure. Clin Chem 58(1):127\u2013138","journal-title":"Clin Chem"},{"issue":"4\u20135","key":"9807_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clinbiochem.2007.07.002","volume":"41","author":"WH Tang","year":"2008","unstructured":"Tang WH et al (2008) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 41(4\u20135):210\u2013221","journal-title":"Clin Biochem"},{"issue":"12","key":"9807_CR18","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","volume":"1832","author":"HK Gaggin","year":"2013","unstructured":"Gaggin HK, Jr JJ (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832(12):2442\u20132450","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"9807_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jacc.2005.11.030","volume":"47","author":"Y Iwanaga","year":"2006","unstructured":"Iwanaga Y et al (2006) B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 47(4):742\u2013748","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"9807_CR20","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1161\/CIRCULATIONAHA.112.129437","volume":"126","author":"TJ Wang","year":"2012","unstructured":"Wang TJ et al (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 126(13):1596\u20131604","journal-title":"Circulation"},{"issue":"3","key":"9807_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ijcard.2006.12.076","volume":"124","author":"LB Daniels","year":"2008","unstructured":"Daniels LB et al (2008) Use of natriuretic peptides in pre-participation screening of college athletes. Int J Cardiol 124(3):411\u2013414","journal-title":"Int J Cardiol"},{"issue":"3","key":"9807_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMoa020233","volume":"347","author":"AS Maisel","year":"2002","unstructured":"Maisel AS et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161\u2013167","journal-title":"N Engl J Med"},{"issue":"3","key":"9807_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/archinte.166.3.315","volume":"166","author":"JL Januzzi Jr","year":"2006","unstructured":"Januzzi JL Jr et al (2006) Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 166(3):315\u2013320","journal-title":"Arch Intern Med"},{"issue":"1","key":"9807_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.acvd.2011.10.007","volume":"105","author":"JL Januzzi Jr","year":"2012","unstructured":"Januzzi JL Jr (2012) The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 105(1):40\u201350","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"9807_CR25","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/j.crvasa.2013.03.010","volume":"55","author":"J Krupicka","year":"2013","unstructured":"Krupicka J, Janota T, Hradec J (2013) Natriuretic peptides in heart failure. Cor Et Vasa 55(4):e370\u2013e376","journal-title":"Cor Et Vasa"},{"issue":"s1","key":"9807_CR26","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1751-7133.2012.00307.x","volume":"18","author":"PS Pang","year":"2012","unstructured":"Pang PS et al (2012) The role of natriuretic peptides: from the emergency department throughout hospitalization. Congestive Heart Fail 18(s1):S5\u2013S8","journal-title":"Congestive Heart Fail"},{"issue":"8","key":"9807_CR27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.amjcard.2010.12.018","volume":"107","author":"HJ Michtalik","year":"2011","unstructured":"Michtalik HJ et al (2011) Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 107(8):1191\u20131195","journal-title":"Am J Cardiol"},{"issue":"17","key":"9807_CR28","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1093\/eurheartj\/ehs136","volume":"33","author":"RV Shah","year":"2012","unstructured":"Shah RV et al (2012) Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 33(17):2197\u20132205","journal-title":"Eur Heart J"},{"issue":"23","key":"9807_CR29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1093\/eurheartj\/ehu090","volume":"35","author":"RW Troughton","year":"2014","unstructured":"Troughton RW et al (2014) Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 35(23):1559\u20131567","journal-title":"Eur Heart J"},{"issue":"18","key":"9807_CR30","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","volume":"58","author":"JL Januzzi Jr","year":"2011","unstructured":"Januzzi JL Jr et al (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58(18):1881\u20131889","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"9807_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cardfail.2011.04.012","volume":"17","author":"MR Shah","year":"2011","unstructured":"Shah MR et al (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17(8):613\u2013621","journal-title":"J Card Fail"},{"issue":"3","key":"9807_CR32","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/eurjhf\/hfs180","volume":"15","author":"RB Weiner","year":"2013","unstructured":"Weiner RB et al (2013) Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 15(3):342\u2013351","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"9807_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jchf.2013.02.004","volume":"1","author":"M Richards","year":"2013","unstructured":"Richards M et al (2013) Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail 1(3):192\u2013199","journal-title":"JACC Heart Fail"},{"issue":"8","key":"9807_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker GM et al (2017) Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318(8):713\u2013720","journal-title":"JAMA"},{"issue":"1","key":"9807_CR35","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"L Mark","year":"2013","unstructured":"Mark L et al (2013) Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA:the Journal of the American Medical Association 310(1):66\u201374","journal-title":"JAMA:the Journal of the American Medical Association"},{"issue":"15","key":"9807_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","volume":"62","author":"H Martin","year":"2013","unstructured":"Martin H et al (2013) PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 62(15):1365\u20131372","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9807_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert KC, Kempf T, Wallentin L (2017) Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin Chem 63(1):140\u2013151","journal-title":"Clin Chem"},{"issue":"55","key":"9807_CR38","doi-asserted-by":"publisher","first-page":"94393","DOI":"10.18632\/oncotarget.21765","volume":"8","author":"BF Peake","year":"2017","unstructured":"Peake BF et al (2017) Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling. Oncotarget 8(55):94393\u201394406","journal-title":"Oncotarget"},{"key":"9807_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijcard.2016.10.038","volume":"226","author":"M Boulogne","year":"2017","unstructured":"Boulogne M et al (2017) Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol 226:53\u201359","journal-title":"Int J Cardiol"},{"issue":"1","key":"9807_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jss.2005.07.036","volume":"130","author":"TA Zimmers","year":"2006","unstructured":"Zimmers TA et al (2006) Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 130(1):45\u201351","journal-title":"J Surg Res"},{"issue":"3","key":"9807_CR41","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.RES.0000202805.73038.48","volume":"98","author":"T Kempf","year":"2006","unstructured":"Kempf T et al (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia\/reperfusion injury. Circ Res 98(3):351\u2013360","journal-title":"Circ Res"},{"key":"9807_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5772\/62797","volume":"5","author":"AE Berezin","year":"2016","unstructured":"Berezin AE (2016) Prognostication in different heart failure phenotypes: the role of circulating biomarkers. J Circ Biomark 5:6","journal-title":"J Circ Biomark"},{"issue":"10","key":"9807_CR43","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jchf.2017.07.013","volume":"5","author":"A Sharma","year":"2017","unstructured":"Sharma A et al (2017) Utility of growth differentiation factor-15, a marker of oxidative stress and inflammation, in chronic heart failure: insights from the HF-ACTION study. JACC Heart Fail 5(10):724\u2013734","journal-title":"JACC Heart Fail"},{"issue":"9324","key":"9807_CR44","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/S0140-6736(02)09093-1","volume":"359","author":"DA Brown","year":"2002","unstructured":"Brown DA et al (2002) Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 359(9324):2159\u20132163","journal-title":"Lancet"},{"issue":"11","key":"9807_CR45","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf T et al (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50(11):1054\u20131060","journal-title":"J Am Coll Cardiol"},{"issue":"412","key":"9807_CR46","doi-asserted-by":"publisher","first-page":"eaan8732","DOI":"10.1126\/scitranslmed.aan8732","volume":"9","author":"Y Xiong","year":"2017","unstructured":"Xiong Y et al (2017) Long-acting MIC-1\/GDF15 molecules to treat obesity: evidence from mice to monkeys. Sci Transl Med 9(412):eaan8732","journal-title":"Sci Transl Med"},{"issue":"1","key":"9807_CR47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/ATVBAHA.110.213512","volume":"31","author":"MP Bonaca","year":"2011","unstructured":"Bonaca MP et al (2011) Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 31(1):203\u2013210","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"9807_CR48","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1164\/rccm.200802-235OC","volume":"178","author":"N Nils","year":"2008","unstructured":"Nils N et al (2008) Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178(5):534\u2013541","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"9807_CR49","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1164\/rccm.200712-1786OC","volume":"177","author":"L Mareike","year":"2008","unstructured":"Mareike L et al (2008) Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med 177(9):1018","journal-title":"Am J Respir Crit Care Med"},{"key":"9807_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cca.2015.03.033","volume":"445","author":"M Thomas","year":"2015","unstructured":"Thomas M et al (2015) Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta 445:155\u2013160","journal-title":"Clin Chim Acta"},{"issue":"7","key":"9807_CR51","first-page":"607","volume":"50","author":"JJ Jr","year":"2007","unstructured":"Jr JJ et al (2007) Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Digest World Core Med J 50(7):607\u2013613","journal-title":"Digest World Core Med J"},{"issue":"4","key":"9807_CR52","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1373\/clinchem.2007.096560","volume":"54","author":"T Mueller","year":"2008","unstructured":"Mueller T et al (2008) Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 54(4):752\u2013756","journal-title":"Clin Chem"},{"issue":"3","key":"9807_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1093\/eurjhf\/hfs006","volume":"14","author":"K Broch","year":"2012","unstructured":"Broch K et al (2012) Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 14(3):268","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9807_CR54","doi-asserted-by":"publisher","first-page":"e000750","DOI":"10.1136\/openhrt-2017-000750","volume":"5","author":"D Binas","year":"2018","unstructured":"Binas D et al (2018) The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart 5(1):e000750","journal-title":"Open Heart"},{"issue":"5","key":"9807_CR55","doi-asserted-by":"crossref","first-page":"e004446","DOI":"10.1161\/CIRCHEARTFAILURE.117.004446","volume":"11","author":"E O'Meara","year":"2018","unstructured":"O'Meara E et al (2018) Independent prognostic value of serum soluble ST2 measurements in patients with heart failure and a reduced ejection fraction in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail 11(5):e004446","journal-title":"Circ Heart Fail"},{"issue":"7 Suppl","key":"9807_CR56","doi-asserted-by":"publisher","first-page":"8b","DOI":"10.1016\/j.amjcard.2015.01.035","volume":"115","author":"T Mueller","year":"2015","unstructured":"Mueller T, Jaffe AS (2015) Soluble ST2\u2014analytical considerations. Am J Cardiol 115(7 Suppl):8b\u201321b","journal-title":"Am J Cardiol"},{"issue":"3","key":"9807_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijcard.2011.05.081","volume":"150","author":"T Ueland","year":"2011","unstructured":"Ueland T et al (2011) Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 150(3):361\u2013364","journal-title":"Int J Cardiol"},{"issue":"14","key":"9807_CR58","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","volume":"60","author":"JE Ho","year":"2012","unstructured":"Ho JE et al (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60(14):1249\u20131256","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9807_CR59","first-page":"181","volume":"64","author":"M Leone","year":"2016","unstructured":"Leone M, Iacoviello M (2016) The predictive value of plasma biomarkers in discharged heart failure patients: role of galectin-3. Minerva Cardioangiol 64(2):181\u2013194","journal-title":"Minerva Cardioangiol"},{"issue":"3","key":"9807_CR60","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.hfc.2014.04.005","volume":"10","author":"KS Shah","year":"2014","unstructured":"Shah KS, Maisel AS (2014) Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 10(3):471\u2013479","journal-title":"Heart Fail Clin"},{"issue":"12","key":"9807_CR61","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/ejhf.407","volume":"17","author":"WC Meijers","year":"2015","unstructured":"Meijers WC et al (2015) Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail 17(12):1271\u20131282","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9807_CR62","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu L et al (2013) Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6(1):107\u2013117","journal-title":"Circ Heart Fail"},{"issue":"4","key":"9807_CR63","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1161\/CIRCHEARTFAILURE.113.000382","volume":"6","author":"RA Weir","year":"2013","unstructured":"Weir RA et al (2013) Response to letter regarding article. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail 6(4):e58","journal-title":"Circ Heart Fail"},{"issue":"9","key":"9807_CR64","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1177\/2047487314552797","volume":"22","author":"V Srivatsan","year":"2015","unstructured":"Srivatsan V, George M, Shanmugam E (2015) Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand? Eur J Prev Cardiol 22(9):1096\u20131110","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"9807_CR65","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12265-013-9467-y","volume":"6","author":"J Hartupee","year":"2013","unstructured":"Hartupee J, Mann DL (2013) Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res 6(4):485\u2013492","journal-title":"J Cardiovasc Transl Res"},{"issue":"10","key":"9807_CR66","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","volume":"69","author":"A Mantel","year":"2017","unstructured":"Mantel A et al (2017) Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure. J Am Coll Cardiol 69(10):1275\u20131285","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"9807_CR67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/hrt.63.4.228","volume":"63","author":"M Pye","year":"1990","unstructured":"Pye M, Rae AP, Cobbe SM (1990) Study of serum C-reactive protein concentration in cardiac failure. Br Heart J 63(4):228\u2013230","journal-title":"Br Heart J"},{"issue":"9","key":"9807_CR68","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1161\/01.CIR.103.9.1194","volume":"103","author":"TP Zwaka","year":"2001","unstructured":"Zwaka TP, Hombach V, Torzewski J (2001) C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103(9):1194\u20131197","journal-title":"Circulation"},{"issue":"2","key":"9807_CR69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","volume":"113","author":"BW Van Tassell","year":"2014","unstructured":"Van Tassell BW et al (2014) Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113(2):321\u2013327","journal-title":"Am J Cardiol"},{"key":"9807_CR70","doi-asserted-by":"publisher","first-page":"012124","DOI":"10.1088\/1755-1315\/125\/1\/012124","volume":"125","author":"Nursyamsiah","year":"2018","unstructured":"Nursyamsiah, Hasan R (2018) High-sensitivity c-reactive protein (hs-CRP) value with 90 days mortality in patients with heart failure. IOP Conference Series: Earth and Environmental Science 125:012124","journal-title":"IOP Conference Series: Earth and Environmental Science"},{"issue":"16","key":"9807_CR71","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1471-2261-14-67","volume":"64","author":"X Li","year":"2014","unstructured":"Li X et al (2014) GW25-e3420 plasma NT pro-BNP, hs-CRP and big-ET levels at admission as prognostic markers of survival in hospitalized patients with dilated cardiomyopathy: a single-center cohort study. BMC Cardiovasc Disord 64(16):67","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"9807_CR72","first-page":"1","volume":"62","author":"J Kjekshus","year":"2008","unstructured":"Kjekshus J, Apetrei E, Barrios V, B\u00f6hm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, J\u00e1nosi A, Kamensk\u00fd G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group (2008) Rosuvastatin in older patients with systolic heart failure. Int J Clin Pract 62(1):1\u20131","journal-title":"Int J Clin Pract"},{"issue":"9","key":"9807_CR73","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1373\/clinchem.2008.105387","volume":"54","author":"MP Bonaca","year":"2008","unstructured":"Bonaca MP, Morrow DA (2008) Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 54(9):1424\u20131431","journal-title":"Clin Chem"},{"issue":"9","key":"9807_CR74","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.110.226936","volume":"108","author":"DL Mann","year":"2011","unstructured":"Mann DL (2011) The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 108(9):1133\u20131145","journal-title":"Circ Res"},{"issue":"4","key":"9807_CR75","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/hrt.2002.007005","volume":"90","author":"SD Anker","year":"2004","unstructured":"Anker SD, Von HS (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90(4):464","journal-title":"Heart"},{"issue":"22","key":"9807_CR76","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","volume":"135","author":"SL Chow","year":"2017","unstructured":"Chow SL et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135(22):e1054","journal-title":"Circulation"},{"issue":"1","key":"9807_CR77","doi-asserted-by":"publisher","first-page":"e001633","DOI":"10.1161\/CIRCGENETICS.116.001633","volume":"10","author":"C Hage","year":"2017","unstructured":"Hage C et al (2017) Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach. Circ Cardiovasc Genet 10(1):e001633","journal-title":"Circ Cardiovasc Genet"},{"issue":"19","key":"9807_CR78","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","volume":"55","author":"A Kalogeropoulos","year":"2010","unstructured":"Kalogeropoulos A et al (2010) Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 55(19):2129\u20132137","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"9807_CR79","doi-asserted-by":"crossref","first-page":"e004373","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","volume":"10","author":"BW Van Tassell","year":"2017","unstructured":"Van Tassell BW et al (2017) Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ Heart Fail 10(11):e004373","journal-title":"Circ Heart Fail"},{"issue":"5","key":"9807_CR80","doi-asserted-by":"publisher","first-page":"H2098","DOI":"10.1152\/ajpheart.00097.2005","volume":"290","author":"PS Petkova-Kirova","year":"2006","unstructured":"Petkova-Kirova PS et al (2006) Electrical remodeling of cardiac myocytes from mice with heart failure due to the overexpression of tumor necrosis factor-alpha. Am J Physiol Heart Circ Physiol 290(5):H2098\u2013H2107","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"9807_CR81","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","volume":"103","author":"B Bozkurt","year":"2001","unstructured":"Bozkurt B et al (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103(8):1044\u20131047","journal-title":"Circulation"},{"issue":"2","key":"9807_CR82","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/jcp.20307","volume":"204","author":"S Fredj","year":"2005","unstructured":"Fredj S et al (2005) Role of interleukin-6 in cardiomyocyte\/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J Cell Physiol 204(2):428\u2013436","journal-title":"J Cell Physiol"},{"issue":"Suppl 2","key":"9807_CR83","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar1917","volume":"8","author":"C Gabay","year":"2006","unstructured":"Gabay C (2006) Interleukin-6 and chronic inflammation. Arthritis Res Ther 8(Suppl 2):S3","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"9807_CR84","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/1742-2094-10-140","volume":"10","author":"F Fuchs","year":"2013","unstructured":"Fuchs F et al (2013) Activation of the inflammatory transcription factor nuclear factor interleukin-6 during inflammatory and psychological stress in the brain. J Neuroinflammation 10(1):905","journal-title":"J Neuroinflammation"},{"issue":"6","key":"9807_CR85","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/01.RES.0000141528.54850.bd","volume":"95","author":"Y Li","year":"2004","unstructured":"Li Y et al (2004) Critical roles for the Fas\/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ Res 95(6):627\u2013636","journal-title":"Circ Res"},{"issue":"12","key":"9807_CR86","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/S0002-9149(97)00228-2","volume":"79","author":"M Okuyama","year":"1997","unstructured":"Okuyama M et al (1997) Serum levels of soluble form of Fas molecule in patients with congestive heart failure. Am J Cardiol 79(12):1698\u20131701","journal-title":"Am J Cardiol"},{"issue":"10","key":"9807_CR87","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S0002-9149(99)00133-2","volume":"83","author":"S Yamaguchi","year":"1999","unstructured":"Yamaguchi S et al (1999) Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. Am J Cardiol 83(10):1500\u20131503","journal-title":"Am J Cardiol"},{"issue":"3","key":"9807_CR88","first-page":"245","volume":"1","author":"MS Bedi","year":"2008","unstructured":"Bedi MS et al (2008) Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support. ClinTransl Sci 1(3):245\u2013248","journal-title":"ClinTransl Sci"},{"issue":"4","key":"9807_CR89","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3343\/alm.2014.34.4.263","volume":"34","author":"M Meisner","year":"2014","unstructured":"Meisner M (2014) Update on procalcitonin measurements. Ann Lab Med 34(4):263\u2013273","journal-title":"Ann Lab Med"},{"issue":"4","key":"9807_CR90","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ajem.2013.12.045","volume":"32","author":"F Travaglino","year":"2014","unstructured":"Travaglino F et al (2014) Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial. Am J Emerg Med 32(4):334\u2013341","journal-title":"Am J Emerg Med"},{"issue":"1","key":"9807_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/cc13174","volume":"18","author":"W Wang","year":"2014","unstructured":"Wang W et al (2014) Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit Care 18(1):1\u20139","journal-title":"Crit Care"},{"key":"9807_CR92","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2015.11.141","volume":"204","author":"BG Demissei","year":"2016","unstructured":"Demissei BG et al (2016) Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. Int J Cardiol 204:164\u2013171","journal-title":"Int J Cardiol"},{"issue":"3","key":"9807_CR93","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1093\/eurjhf\/hfr177","volume":"14","author":"A Maisel","year":"2012","unstructured":"Maisel A et al (2012) Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur J Heart Fail 14(3):278\u2013286","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9807_CR94","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amjmed.2015.06.037","volume":"129","author":"GA Alba","year":"2016","unstructured":"Alba GA et al (2016) Diagnostic and prognostic utility of procalcitonin in patients presenting to the emergency department with dyspnea. Am J Med 129(1):96\u2013104.e7","journal-title":"Am J Med"},{"key":"9807_CR95","doi-asserted-by":"crossref","unstructured":"Berezin AE (2018) Circulating biomarkers in heart failure. Adv Exp Med Biol 1067:89\u2013108","DOI":"10.1007\/5584_2017_140"},{"issue":"suppl_7","key":"9807_CR96","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G et al (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 23(suppl_7):155","journal-title":"Ann Oncol"},{"issue":"2","key":"9807_CR97","first-page":"69","volume":"113","author":"K Thygesen","year":"2013","unstructured":"Thygesen K et al (2013) Third universal definition of myocardial infarction. Glob Heart 113(2):69\u201370","journal-title":"Glob Heart"},{"issue":"9","key":"9807_CR98","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"H Sawaya","year":"2011","unstructured":"Sawaya H et al (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107(9):1375\u20131380","journal-title":"Am J Cardiol"},{"issue":"11","key":"9807_CR99","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1161\/CIRCULATIONAHA.106.655076","volume":"116","author":"R Latini","year":"2007","unstructured":"Latini R et al (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116(11):1242\u20131249","journal-title":"Circulation"},{"issue":"7","key":"9807_CR100","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/01.CIR.0000084543.79097.34","volume":"108","author":"TB Horwich","year":"2003","unstructured":"Horwich TB et al (2003) Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108(7):833\u2013838","journal-title":"Circulation"},{"issue":"3","key":"9807_CR101","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.ahj.2003.10.014","volume":"147","author":"MP Hudson","year":"2004","unstructured":"Hudson MP et al (2004) Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 147(3):546\u2013552","journal-title":"Am Heart J"},{"issue":"7","key":"9807_CR102","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/S1053-2498(00)00120-0","volume":"19","author":"L La Vecchia","year":"2000","unstructured":"La Vecchia L et al (2000) Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 19(7):644\u2013652","journal-title":"J Heart Lung Transplant"},{"issue":"20","key":"9807_CR103","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa0706824","volume":"358","author":"WF Peacock","year":"2008","unstructured":"Peacock WF et al (2008) Cardiac troponin and outcome in acute heart failure. N Engl J Med 358(20):2117\u20132126","journal-title":"N Engl J Med"},{"issue":"7","key":"9807_CR104","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/eurjhf\/hfr049","volume":"13","author":"I Tentzeris","year":"2011","unstructured":"Tentzeris I et al (2011) Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 13(7):726\u2013733","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9807_CR105","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/eurjhf\/hfq210","volume":"13","author":"Y Xue","year":"2011","unstructured":"Xue Y et al (2011) Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 13(1):37\u201342","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"9807_CR106","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijcard.2011.10.113","volume":"166","author":"S Ather","year":"2013","unstructured":"Ather S et al (2013) Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol 166(2):394\u2013398","journal-title":"Int J Cardiol"},{"issue":"3","key":"9807_CR107","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1161\/01.CIR.103.3.369","volume":"103","author":"Y Sato","year":"2001","unstructured":"Sato Y et al (2001) Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103(3):369\u2013374","journal-title":"Circulation"},{"issue":"1","key":"9807_CR108","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/BF03194597","volume":"47","author":"A Chmurzynska","year":"2006","unstructured":"Chmurzynska A (2006) The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 47(1):39\u201348","journal-title":"J Appl Genet"},{"key":"9807_CR109","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/B978-0-12-415759-0.00046-7","volume":"III","author":"B Berridge","year":"2013","unstructured":"Berridge B, Van Vleet JF, Herman E (2013) Cardiac, vascular, and skeletal muscle systems. Haschek and Rousseaux's Handbook Toxicol Pathol III:1567\u20131665","journal-title":"Haschek and Rousseaux's Handbook Toxicol Pathol"},{"issue":"23","key":"9807_CR110","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.jacc.2009.12.062","volume":"55","author":"K Viswanathan","year":"2010","unstructured":"Viswanathan K et al (2010) Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol 55(23):2590\u20132598","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9807_CR111","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.106.641936","volume":"114","author":"M O'Donoghue","year":"2006","unstructured":"O'Donoghue M et al (2006) Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation 114(6):550\u2013557","journal-title":"Circulation"},{"issue":"9","key":"9807_CR112","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0002-9343(02)01394-3","volume":"113","author":"K Setsuta","year":"2002","unstructured":"Setsuta K et al (2002) Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 113(9):717\u2013722","journal-title":"Am J Med"},{"issue":"9","key":"9807_CR113","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clinbiochem.2017.02.014","volume":"50","author":"T Kitai","year":"2017","unstructured":"Kitai T et al (2017) Circulating intestinal fatty acid-binding protein (I-FABP) levels in acute decompensated heart failure. Clin Biochem 50(9):491\u2013495","journal-title":"Clin Biochem"},{"issue":"6","key":"9807_CR114","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.amjms.2016.08.018","volume":"352","author":"HY Qian","year":"2016","unstructured":"Qian HY et al (2016) Heart-type fatty acid binding protein in the assessment of acute pulmonary embolism. Am J Med Sci 352(6):557\u2013562","journal-title":"Am J Med Sci"},{"key":"9807_CR115","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.acc.2016.09.002","volume":"79","author":"A Savic-Radojevic","year":"2017","unstructured":"Savic-Radojevic A et al (2017) Novel biomarkers of heart failure. Adv Clin Chem 79:93\u2013152","journal-title":"Adv Clin Chem"},{"issue":"Suppl 1","key":"9807_CR116","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.3949\/ccjm.78.s1.13","volume":"78","author":"GS Francis","year":"2011","unstructured":"Francis GS (2011) Neurohormonal control of heart failure. Cleve Clin J Med 78(Suppl 1):S75\u2013S79","journal-title":"Cleve Clin J Med"},{"key":"9807_CR117","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJM196209272671305","volume":"267","author":"CA Chidsey","year":"1962","unstructured":"Chidsey CA, Harrison DC, Braunwald E (1962) Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med 267:650\u2013654","journal-title":"N Engl J Med"},{"issue":"13","key":"9807_CR118","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJM198409273111303","volume":"311","author":"JN Cohn","year":"1984","unstructured":"Cohn JN et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311(13):819\u2013823","journal-title":"N Engl J Med"},{"issue":"1","key":"9807_CR119","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","volume":"20","author":"M Packer","year":"1992","unstructured":"Packer M (1992) The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 20(1):248\u2013254","journal-title":"J Am Coll Cardiol"},{"key":"9807_CR120","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","volume":"25","author":"R Latini","year":"2004","unstructured":"Latini R et al (2004) The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25:292\u2013299","journal-title":"Eur Heart J"},{"issue":"4","key":"9807_CR121","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ehj.2003.12.013","volume":"25","author":"MM Givertz","year":"2004","unstructured":"Givertz MM, Braunwald E (2004) Neurohormones in heart failure: predicting outcomes, optimizing care. Eur Heart J 25(4):281","journal-title":"Eur Heart J"},{"issue":"4","key":"9807_CR122","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamacardio.2016.0962","volume":"1","author":"MD Jankowich","year":"2016","unstructured":"Jankowich MD, Wu W, Choudhary G (2016) Association of elevated plasma endothelin-1 levels with pulmonary hypertension, mortality, and heart failure in African American individuals: the Jackson Heart Study. JAMA Cardiol 1(4):461\u2013469","journal-title":"JAMA Cardiol"},{"issue":"8","key":"9807_CR123","doi-asserted-by":"crossref","first-page":"824","DOI":"10.23736\/S0375-9393.17.10882-5","volume":"83","author":"C Ara-Somohano","year":"2017","unstructured":"Ara-Somohano C et al (2017) Evaluation of eight biomarkers to predict short-term mortality in patients with acute severe dyspnea. Minerva Anestesiol 83(8):824\u2013835","journal-title":"Minerva Anestesiol"},{"issue":"4","key":"9807_CR124","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/BF02696649","volume":"2","author":"JR Teerlink","year":"2005","unstructured":"Teerlink JR (2005) Endothelins: pathophysiology and treatment implications in chronic heart failure. Current Heart Failure Reports 2(4):191\u2013197","journal-title":"Current Heart Failure Reports"},{"issue":"3","key":"9807_CR125","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bbrc.2012.08.022","volume":"425","author":"K Kitamura","year":"2012","unstructured":"Kitamura K et al (2012) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 425(3):553\u2013560","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"9807_CR126","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.clinbiochem.2014.01.032","volume":"47","author":"ME Liquori","year":"2014","unstructured":"Liquori ME et al (2014) Cardiac biomarkers in heart failure. Clin Biochem 47(6):327\u2013337","journal-title":"Clin Biochem"},{"issue":"13","key":"9807_CR127","doi-asserted-by":"publisher","first-page":"E948","DOI":"10.1016\/S0735-1097(12)60949-8","volume":"59","author":"R Shah","year":"2012","unstructured":"Shah R et al (2012) Mid-regional pro-atrial natriuretic peptide and mid-regional pro-adrenomedullin are valuable for the evaluation of patients with acute dyspnea: results from the Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardiol 59(13):E948\u2013E948","journal-title":"J Am Coll Cardiol"},{"key":"9807_CR128","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.08.012","volume":"312","author":"A Bustamante","year":"2017","unstructured":"Bustamante A et al (2017) Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol 312:19\u201323","journal-title":"J Neuroimmunol"},{"issue":"19","key":"9807_CR129","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.jacc.2010.02.025","volume":"55","author":"A Maisel","year":"2010","unstructured":"Maisel A et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55(19):2062\u20132076","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9807_CR130","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12872-017-0605-3","volume":"17","author":"J Odermatt","year":"2017","unstructured":"Odermatt J et al (2017) Pro-Adrenomedullin predicts 10-year all-cause mortality in community-dwelling patients: a prospective cohort study. BMC Cardiovasc Disord 17(1):178","journal-title":"BMC Cardiovasc Disord"},{"key":"9807_CR131","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2147\/COPD.S126400","volume":"12","author":"M Dres","year":"2017","unstructured":"Dres M et al (2017) Mid-regional pro-adrenomedullin and copeptin to predict short-term prognosis of COPD exacerbations: a multicenter prospective blinded study. International Journal of Chronic Obstructive Pulmonary Disease 12:1047\u20131056","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"19","key":"9807_CR132","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1161\/01.CIR.97.19.1921","volume":"97","author":"AM Richards","year":"1998","unstructured":"Richards AM et al (1998) Plasma N-terminal pro\u2013brain natriuretic peptide and adrenomedullin. Circulation 97(19):1921\u20131929","journal-title":"Circulation"},{"issue":"2","key":"9807_CR133","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/ejhf.988","volume":"20","author":"P Welsh","year":"2018","unstructured":"Welsh P et al (2018) Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail 20(2):268\u2013277","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"9807_CR134","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.amjmed.2006.05.007","volume":"119","author":"RW Schrier","year":"2006","unstructured":"Schrier RW (2006) Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 119(7):S47\u2013S53","journal-title":"Am J Med"},{"issue":"5","key":"9807_CR135","first-page":"613","volume":"55","author":"A Maisel","year":"2011","unstructured":"Maisel A et al (2011) Increased 90-day mortality in patients with acute heart failure with elevated copeptin clinical perspective. J Am Coll Cardiol 55(5):613","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9807_CR136","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1161\/CIRCULATIONAHA.111.063842","volume":"125","author":"MS Sabatine","year":"2012","unstructured":"Sabatine MS et al (2012) Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 125(2):233\u2013240","journal-title":"Circulation"},{"issue":"10","key":"9807_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HJH.0000000000001041","volume":"34","author":"H Remde","year":"2016","unstructured":"Remde H et al (2016) The cardiovascular markers copeptin and high-sensitive C-reactive protein decrease following specific therapy for primary aldosteronism. J Hypertens 34(10):1","journal-title":"J Hypertens"},{"issue":"7","key":"9807_CR138","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1042\/CS20160196","volume":"131","author":"Y Moayedi","year":"2017","unstructured":"Moayedi Y, Ross HJ (2017) Advances in heart failure: a review of biomarkers, emerging pharmacological therapies, durable mechanical support and telemonitoring. Clin Sci 131(7):553","journal-title":"Clin Sci"},{"issue":"9","key":"9807_CR139","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/jcmm.13102","volume":"21","author":"JJ Yan","year":"2017","unstructured":"Yan JJ et al (2017) Predictive value of plasma copeptin level for the risk and mortality of heart failure: a meta-analysis. J Cell Mol Med 21(9):1815\u20131825","journal-title":"J Cell Mol Med"},{"issue":"1","key":"9807_CR140","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/clc.22602","volume":"40","author":"I Sahin","year":"2016","unstructured":"Sahin I et al (2016) Higher copeptin levels are associated with worse outcome in patients with hypertrophic cardiomyopathy. Clin Cardiol 40(1):32\u201337","journal-title":"Clin Cardiol"},{"issue":"10","key":"9807_CR141","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jacc.2004.01.028","volume":"43","author":"J Hokamaki","year":"2004","unstructured":"Hokamaki J et al (2004) Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 43(10):1880\u20131885","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"9807_CR142","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/eurheartj\/14.11.1493","volume":"14","author":"J Mcmurray","year":"1993","unstructured":"Mcmurray J et al (1993) Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14(11):1493\u20131498","journal-title":"Eur Heart J"},{"issue":"2","key":"9807_CR143","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1071-9164(00)90012-5","volume":"6","author":"S Mak","year":"2000","unstructured":"Mak S et al (2000) Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J Card Fail 6(2):108\u2013114","journal-title":"J Card Fail"},{"issue":"24","key":"9807_CR144","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1161\/01.CIR.0000106903.98196.B6","volume":"108","author":"WHW Tang","year":"2003","unstructured":"Tang WHW et al (2003) Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108(24):2964\u20132966","journal-title":"Circulation"},{"issue":"4","key":"9807_CR145","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ahj.2008.12.017","volume":"157","author":"JA de Lemos","year":"2009","unstructured":"de Lemos JA et al (2009) Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. Am Heart J 157(4):746\u2013753 e2","journal-title":"Am Heart J"},{"issue":"7","key":"9807_CR146","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0735-1097(01)01269-4","volume":"37","author":"AM Richards","year":"2001","unstructured":"Richards AM et al (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37(7):1781\u20131787","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9807_CR147","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2005.09.025","volume":"47","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC et al (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47(2):345\u2013353","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"9807_CR148","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1093\/eurheartj\/ehl406","volume":"27","author":"H Scharling","year":"2006","unstructured":"Scharling H et al (2006) Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 27(24):3004\u20133010","journal-title":"Eur Heart J"},{"issue":"12","key":"9807_CR149","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.4065\/mcp.2011.0437","volume":"86","author":"PM McKie","year":"2011","unstructured":"McKie PM et al (2011) Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc 86(12):1154\u20131160","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"9807_CR150","first-page":"330","volume":"27","author":"A Bayes-Genis","year":"2005","unstructured":"Bayes-Genis A et al (2005) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27(3):330\u2013337","journal-title":"Eur Heart J"},{"issue":"2","key":"9807_CR151","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/heartjnl-2013-303632","volume":"100","author":"K Salah","year":"2014","unstructured":"Salah K et al (2014) A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: \u00c9LAN-HF Score. Heart 100(2):115\u2013125","journal-title":"Heart"},{"issue":"20","key":"9807_CR152","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.jacc.2007.08.012","volume":"50","author":"S von Haehling","year":"2007","unstructured":"von Haehling S et al (2007) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50(20):1973\u20131980","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"9807_CR153","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/europace\/euw305","volume":"19","author":"H Tolppanen","year":"2017","unstructured":"Tolppanen H et al (2017) Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. EP Europace 19(11):1848\u20131854","journal-title":"EP Europace"},{"issue":"5","key":"9807_CR154","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/heartjnl-2011-300823","volume":"98","author":"Wayne L Miller","year":"2011","unstructured":"Miller WL et al (2012) Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 98(5): p. 389-94.\u00a0","journal-title":"Heart"},{"issue":"2","key":"9807_CR155","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/03009734.2018.1460427","volume":"123","author":"S Doerstling","year":"2018","unstructured":"Doerstling S et al (2018) Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact. Ups J Med Sci 123(2):86\u201393","journal-title":"Ups J Med Sci"},{"issue":"18","key":"9807_CR156","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.jacc.2012.12.048","volume":"61","author":"KM Eggers","year":"2013","unstructured":"Eggers KM et al (2013) Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 61(18):1906\u20131913","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"9807_CR157","doi-asserted-by":"publisher","first-page":"e010364","DOI":"10.1161\/JAHA.118.010364","volume":"7","author":"M Fudim","year":"2018","unstructured":"Fudim M et al (2018) High-sensitivity troponin I in hospitalized and ambulatory patients with heart failure with preserved ejection fraction: insights from the heart failure clinical research network. J Am Heart Assoc 7(24):e010364\u2013e010364","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"9807_CR158","first-page":"230","volume":"112","author":"LTd Castro","year":"2019","unstructured":"Castro LTd et al (2019) Elevated high-sensitivity troponin I in the stabilized phase after an acute coronary syndrome predicts all-cause and cardiovascular mortality in a highly admixed population: a 7-year cohort. Arq Bras Cardiol 112(3):230\u2013237","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"9807_CR159","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cardfail.2004.03.005","volume":"11","author":"T Arimoto","year":"2005","unstructured":"Arimoto T et al (2005) Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail 11(1):56\u201360","journal-title":"J Card Fail"},{"issue":"5","key":"9807_CR160","doi-asserted-by":"publisher","first-page":"e94834","DOI":"10.1371\/journal.pone.0094834","volume":"9","author":"Y Otaki","year":"2014","unstructured":"Otaki Y et al (2014) Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study. PLoS One 9(5):e94834","journal-title":"PLoS One"},{"issue":"5","key":"9807_CR161","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3343\/alm.2016.36.5.420","volume":"36","author":"JH Jeong","year":"2016","unstructured":"Jeong JH et al (2016) The prognostic value of serum levels of heart-type fatty acid binding protein and high sensitivity C-reactive protein in patients with increased levels of amino-terminal pro-B type natriuretic peptide. Ann Lab Med 36(5):420\u2013426","journal-title":"Ann Lab Med"},{"issue":"1","key":"9807_CR162","doi-asserted-by":"publisher","first-page":"14410","DOI":"10.1038\/s41598-018-32210-x","volume":"8","author":"S-K Ho","year":"2018","unstructured":"Ho S-K et al (2018) The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease. Sci Rep 8(1):14410","journal-title":"Sci Rep"},{"issue":"9","key":"9807_CR163","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.amjcard.2009.01.026","volume":"103","author":"WH Tang","year":"2009","unstructured":"Tang WH et al (2009) Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 103(9):1269\u20131274","journal-title":"Am J Cardiol"},{"issue":"6","key":"9807_CR164","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1373\/clinchem.2009.142257","volume":"56","author":"T Reichlin","year":"2010","unstructured":"Reichlin T et al (2010) Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 56(6):944\u2013951","journal-title":"Clin Chem"},{"issue":"2","key":"9807_CR165","first-page":"1595","volume":"13","author":"ML Brennan","year":"2004","unstructured":"Brennan ML, Penn MS, Lente FV (2004) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 13(2):1595\u20131604","journal-title":"N Engl J Med"},{"issue":"1","key":"9807_CR166","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2005.09.020","volume":"152","author":"LL Ng","year":"2006","unstructured":"Ng LL et al (2006) Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 152(1):94\u2013101","journal-title":"Am Heart J"},{"issue":"2","key":"9807_CR167","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S0002-9149(01)02211-1","volume":"89","author":"PF Castro","year":"2002","unstructured":"Castro PF et al (2002) Effects of early decrease in oxidative stress after medical therapy in patients with class IV congestive heart failure. Am J Cardiol 89(2):236\u2013239","journal-title":"Am J Cardiol"},{"issue":"1","key":"9807_CR168","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S0002-8703(96)90063-0","volume":"131","author":"CR D\u00edaz-V\u00e9lez","year":"1996","unstructured":"D\u00edaz-V\u00e9lez CR et al (1996) Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 131(1):146\u2013152","journal-title":"Am Heart J"},{"issue":"6","key":"9807_CR169","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","volume":"2","author":"E Krishnan","year":"2009","unstructured":"Krishnan E (2009) Hyperuricemia and incident heart failure. Circ Heart Fail 2(6):556\u2013562","journal-title":"Circ Heart Fail"},{"issue":"10","key":"9807_CR170","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.amjcard.2016.02.039","volume":"117","author":"A Palazzuoli","year":"2016","unstructured":"Palazzuoli A et al (2016) Prognostic significance of hyperuricemia in patients with acute heart failure. Am J Cardiol 117(10):1616\u20131621","journal-title":"Am J Cardiol"},{"key":"9807_CR171","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2017.11.083","volume":"252","author":"SG Wannamethee","year":"2018","unstructured":"Wannamethee SG et al (2018) Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: the British Regional Heart Study. Int J Cardiol 252:187\u2013192","journal-title":"Int J Cardiol"},{"issue":"2","key":"9807_CR172","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ehf2.12135","volume":"4","author":"A Amin","year":"2017","unstructured":"Amin A et al (2017) On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. Esc Heart Failure 4(2):162\u2013168","journal-title":"Esc Heart Failure"},{"issue":"8","key":"9807_CR173","doi-asserted-by":"publisher","first-page":"e14525","DOI":"10.1097\/MD.0000000000014525","volume":"98","author":"G Huang","year":"2019","unstructured":"Huang G et al (2019) Prognostic value of serum uric acid in patients with acute heart failure: a meta-analysis. Medicine 98(8):e14525\u2013e14525","journal-title":"Medicine"},{"issue":"4","key":"9807_CR174","first-page":"1","volume":"32","author":"H Okazaki","year":"2016","unstructured":"Okazaki H et al (2016) Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart Vessel 32(4):1\u201310","journal-title":"Heart Vessel"},{"issue":"3","key":"9807_CR175","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1388-9842(02)00021-1","volume":"4","author":"JL Alonso-Mart\u00ednez","year":"2002","unstructured":"Alonso-Mart\u00ednez JL et al (2002) C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 4(3):331\u2013336","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"9807_CR176","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.amjcard.2013.10.022","volume":"113","author":"JJ Park","year":"2014","unstructured":"Park JJ et al (2014) Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry). Am J Cardiol 113(3):511\u2013517","journal-title":"Am J Cardiol"},{"issue":"10","key":"9807_CR177","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","volume":"112","author":"IS Anand","year":"2005","unstructured":"Anand IS et al (2005) C-reactive protein in heart failure. Circulation 112(10):1428\u20131434","journal-title":"Circulation"},{"issue":"16","key":"9807_CR178","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","volume":"103","author":"A Deswal","year":"2001","unstructured":"Deswal A et al (2001) Cytokines and cytokine receptors in advanced heart failure. Circulation 103(16):2055\u20132059","journal-title":"Circulation"},{"key":"9807_CR179","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.12659\/MSM.912457","volume":"25","author":"W Liu","year":"2019","unstructured":"Liu W et al (2019) Serum levels of inflammatory cytokines and expression of BCL2 and BAX mRNA in peripheral blood mononuclear cells and in patients with chronic heart failure. Med Sci Monit 25:2633\u20132639","journal-title":"Med Sci Monit"},{"issue":"11","key":"9807_CR180","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","volume":"107","author":"RS Vasan","year":"2003","unstructured":"Vasan RS et al (2003) Inflammatory markers and risk of heart Failure in elderly subjects without prior myocardial infarction. Circulation 107(11):1486\u20131491","journal-title":"Circulation"},{"issue":"4","key":"9807_CR181","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/AC.70.4.3096896","volume":"70","author":"A Canbay","year":"2015","unstructured":"Canbay A et al (2015) Procalcitonin: a marker of heart failure. Acta Cardiol 70(4):473\u2013478","journal-title":"Acta Cardiol"},{"issue":"3","key":"9807_CR182","first-page":"260","volume":"2","author":"T Ahmad","year":"2014","unstructured":"Ahmad T et al (2014) Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC: Heart Failure 2(3):260\u2013268","journal-title":"JACC: Heart Failure"},{"issue":"2","key":"9807_CR183","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jacc.2013.07.087","volume":"63","author":"A Bayes-Genis","year":"2014","unstructured":"Bayes-Genis A et al (2014) Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol 63(2):158\u2013166","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"9807_CR184","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2013.10.005","volume":"2","author":"HK Gaggin","year":"2014","unstructured":"Gaggin HK et al (2014) Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. Jacc Heart Failure 2(1):65","journal-title":"Jacc Heart Failure"},{"issue":"8","key":"9807_CR185","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/eurjhf\/hfq091","volume":"12","author":"RV Shah","year":"2010","unstructured":"Shah RV et al (2010) Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 12(8):826\u2013832","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"9807_CR186","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/07853890.2010.538080","volume":"43","author":"RA Boer","year":"2011","unstructured":"Boer RA (2011) De, et al., Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43(1):60\u201368","journal-title":"Ann Med"},{"issue":"12","key":"9807_CR187","doi-asserted-by":"crossref","first-page":"e003700","DOI":"10.1161\/JAHA.116.003700","volume":"6","author":"LC van Vark","year":"2017","unstructured":"van Vark LC et al (2017) Prognostic value of serial galectin-3 measurements in patients with acute heart failure. J Am Heart Assoc 6(12):e003700","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"9807_CR188","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","volume":"107","author":"IS Anand","year":"2003","unstructured":"Anand IS et al (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9):1278\u20131283","journal-title":"Circulation"},{"issue":"2","key":"9807_CR189","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/CIRCULATIONAHA.106.644286","volume":"115","author":"JH Ix","year":"2007","unstructured":"Ix JH et al (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115(2):173\u2013179","journal-title":"Circulation"},{"issue":"4","key":"9807_CR190","first-page":"72","volume":"17","author":"TH Kim","year":"2015","unstructured":"Kim TH, Kim H, Kim IC (2015) The potential of cystatin-C to evaluate the prognosis of acute heart failure: a comparative study. Int J Cardiovasc Interv 17(4):72\u201376","journal-title":"Int J Cardiovasc Interv"},{"issue":"2","key":"9807_CR191","doi-asserted-by":"publisher","first-page":"BSR20181761","DOI":"10.1042\/BSR20181761","volume":"39","author":"S Chen","year":"2019","unstructured":"Chen S, Tang Y, Zhou X (2019) Cystatin C for predicting all-cause mortality and rehospitalization in patients with heart failure: a meta-analysis. Biosci Rep 39(2):BSR20181761","journal-title":"Biosci Rep"},{"issue":"21","key":"9807_CR192","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/eurheartj\/ehr190","volume":"32","author":"K Damman","year":"2011","unstructured":"Damman K et al (2011) Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J 32(21):2705\u20132712","journal-title":"Eur Heart J"},{"issue":"1","key":"9807_CR193","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCHEARTFAILURE.113.000242","volume":"7","author":"VMV Deursen","year":"2014","unstructured":"Deursen VMV et al (2014) Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circ Heart Fail 7(1):35\u201342","journal-title":"Circ Heart Fail"},{"key":"9807_CR194","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12872-015-0054-9","volume":"15","author":"S Kirbi\u0161","year":"2015","unstructured":"Kirbi\u0161 S, Gorenjak M, Sinkovi\u010d A (2015) The role of urine neutrophil gelatinase-associated lipocalin (NGAL) in acute heart failure in patients with ST-elevation myocardial infarction. BMC Cardiovasc Disord 15:49\u201349","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"9807_CR195","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ejhf.746","volume":"19","author":"M Sokolski","year":"2017","unstructured":"Sokolski M et al (2017) Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur J Heart Fail 19(6):760\u2013767","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"9807_CR196","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jacc.2016.06.055","volume":"68","author":"AS Maisel","year":"2016","unstructured":"Maisel AS et al (2016) Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations : the AKINESIS study. J Am Coll Cardiol 68(13):1420\u20131431","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"9807_CR197","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.3390\/ijms18071470","volume":"18","author":"K Damman","year":"2017","unstructured":"Damman K et al (2017) Plasma neutrophil gelatinase-associated lipocalin and predicting clinically relevant worsening renal function in acute heart failure. Int J Mol Sci 18(7):1470","journal-title":"Int J Mol Sci"},{"issue":"4","key":"9807_CR198","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.hfc.2009.04.003","volume":"5","author":"BH Trachtenberg","year":"2009","unstructured":"Trachtenberg BH, Hare JM (2009) Biomarkers of oxidative stress in heart failure. Heart Fail Clin 5(4):561\u2013577","journal-title":"Heart Fail Clin"},{"issue":"6","key":"9807_CR199","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.amjcard.2006.04.018","volume":"98","author":"WHW Tang","year":"2006","unstructured":"Tang WHW et al (2006) Plasma myeloperoxidase levels in patients with chronic heart Failure. Am J Cardiol 98(6):796\u2013799","journal-title":"Am J Cardiol"},{"issue":"11","key":"9807_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/691693","volume":"2015","author":"A Cabassi","year":"2015","unstructured":"Cabassi A et al (2015) Myeloperoxidase-related chlorination activity is positively associated with circulating ceruloplasmin in chronic heart failure patients: relationship with neurohormonal, inflammatory, and nutritional parameters. Biomed Res Int 2015(11):1\u201310","journal-title":"Biomed Res Int"},{"issue":"1","key":"9807_CR201","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1373\/clinchem.2008.108159","volume":"55","author":"KB Shah","year":"2009","unstructured":"Shah KB et al (2009) Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem 55(1):59\u201367","journal-title":"Clin Chem"},{"key":"9807_CR202","unstructured":"Mann EBDL and Mann DL, Heart failure:a companion to Braunwald\u2019s heart disease. Elsevier\/Saunders"},{"issue":"4","key":"9807_CR203","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/bcp.13855","volume":"85","author":"L-M Gan","year":"2019","unstructured":"Gan L-M et al (2019) Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers. Br J Clin Pharmacol 85(4):762\u2013770","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"9807_CR204","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1161\/CIRCULATIONAHA.106.651117","volume":"114","author":"J George","year":"2006","unstructured":"George J et al (2006) High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114(23):2508\u20132516","journal-title":"Circulation"},{"key":"9807_CR205","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijcard.2016.11.077","volume":"228","author":"Y Otaki","year":"2017","unstructured":"Otaki Y et al (2017) Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol 228:151\u2013157","journal-title":"Int J Cardiol"},{"issue":"24","key":"9807_CR206","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","volume":"51","author":"JM Hare","year":"2008","unstructured":"Hare JM et al (2008) Impact of oxypurinol in patients with symptomatic heart failure: results of the OPT-CHF study. J Am Coll Cardiol 51(24):2301\u20132309","journal-title":"J Am Coll Cardiol"},{"key":"9807_CR207","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijcard.2016.07.225","volume":"222","author":"N Masaki","year":"2016","unstructured":"Masaki N et al (2016) Usefulness of the d-ROMs test for prediction of cardiovascular events. Int J Cardiol 222:226\u2013232","journal-title":"Int J Cardiol"},{"issue":"3","key":"9807_CR208","doi-asserted-by":"publisher","first-page":"153","DOI":"10.14740\/cr733w","volume":"9","author":"T Hitsumoto","year":"2018","unstructured":"Hitsumoto T (2018) Efficacy of the reactive oxygen metabolite test as a predictor of initial heart failure hospitalization in elderly patients with chronic heart failure. Cardiol Res 9(3):153\u2013160","journal-title":"Cardiol Res"},{"issue":"2625","key":"9807_CR209","first-page":"965","volume":"33","author":"DL Mann","year":"2015","unstructured":"Mann DL, Felker MG (2015) Heart Failure. Tex Heart Inst J 33(2625):965","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"9807_CR210","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/chf.12012","volume":"19","author":"MD Hyungseop Kim","year":"2013","unstructured":"Hyungseop Kim MD et al (2013) Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congestive Heart Failure 19(3):123","journal-title":"Congestive Heart Failure"},{"issue":"6","key":"9807_CR211","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.15419\/bmrat.v4i06.178","volume":"4","author":"AE Berezin","year":"2017","unstructured":"Berezin AE (2017) Up-to-date clinical approaches of biomarkers\u2019 use in heart failure. Biomedical Research and Therapy 4(6):1344","journal-title":"Biomedical Research and Therapy"},{"issue":"6","key":"9807_CR212","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ejhf.273","volume":"17","author":"RA de Boer","year":"2015","unstructured":"de Boer RA et al (2015) State of the art: newer biomarkers in heart failure. Eur J Heart Fail 17(6):559\u2013569","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"9807_CR213","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jacc.2011.10.854","volume":"59","author":"TL Nickolas","year":"2012","unstructured":"Nickolas TL et al (2012) Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage. A multicenter prospective cohort study. J Am Coll Cardiol 59(3):246\u2013255","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9807_CR214","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/CIRCHEARTFAILURE.111.965020","volume":"5","author":"B Ky","year":"2012","unstructured":"Ky B et al (2012) Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 5(2):183","journal-title":"Circ Heart Fail"},{"issue":"8","key":"9807_CR215","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ejhf.749","volume":"19","author":"BG Demissei","year":"2017","unstructured":"Demissei BG et al (2017) A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail 19(8):1001\u20131010","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"9807_CR216","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","volume":"55","author":"A Piek","year":"2018","unstructured":"Piek A et al (2018) Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci 55(4):246\u2013263","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"9807_CR217","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/72480","volume":"18","author":"GA Evans","year":"2000","unstructured":"Evans GA (2000) Designer science and the \u201comic\u201d revolution. Nat Biotechnol 18(2):127\u2013120","journal-title":"Nat Biotechnol"},{"issue":"1","key":"9807_CR218","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1373\/clinchem.2016.263350","volume":"63","author":"FS Apple","year":"2017","unstructured":"Apple FS et al (2017) Cardiovascular disease: impact of biomarkers, proteomics, and genomics. Clin Chem 63(1):1\u20134","journal-title":"Clin Chem"},{"issue":"10","key":"9807_CR219","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1074\/mcp.R800007-MCP200","volume":"7","author":"AV Edwards","year":"2008","unstructured":"Edwards AV, White MY, Cordwell SJ (2008) The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 7(10):1824\u20131837","journal-title":"Mol Cell Proteomics"},{"key":"9807_CR220","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1073\/pnas.1017494108","volume":"108","author":"T P Cappola","year":"2011","unstructured":"P Cappola T et al (2011) Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci U S A 108:2456\u20132461","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"9807_CR221","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/eurheartj\/ehr105","volume":"32","author":"E Villard","year":"2011","unstructured":"Villard E et al (2011) Editor\u2019s choice: fast track: a genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J 32(9):1065","journal-title":"Eur Heart J"},{"key":"9807_CR222","first-page":"2","volume":"2","author":"A Berezin","year":"2016","unstructured":"Berezin A (2016) Epigenetically modified endothelial progenitor cells in heart failure. J Clin Epigenet 2:2","journal-title":"J Clin Epigenet"},{"issue":"10","key":"9807_CR223","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/FPC.0000000000000302","volume":"27","author":"DJ Serie","year":"2017","unstructured":"Serie DJ et al (2017) Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial. Pharmacogenet Genomics 27(10):378\u2013385","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"9807_CR224","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/FPC.0000000000000284","volume":"27","author":"QS Wells","year":"2017","unstructured":"Wells QS et al (2017) Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults. Pharmacogenet Genomics 27(7):247","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"9807_CR225","doi-asserted-by":"publisher","first-page":"688","DOI":"10.15252\/emmm.201506174","volume":"8","author":"T Kessler","year":"2016","unstructured":"Kessler T, Vilne B, Schunkert H (2016) The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. Embo Mol Med 8(7):688\u2013701","journal-title":"Embo Mol Med"},{"key":"9807_CR226","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/CIRCRESAHA.115.306566","volume":"118","author":"R McPherson","year":"2016","unstructured":"McPherson R, Tybjaerg-Hansen A (2016) Genetics of coronary artery disease. Circ Res 118:564\u2013578","journal-title":"Circ Res"},{"issue":"2","key":"9807_CR227","first-page":"1","volume":"2015","author":"J Yang","year":"2015","unstructured":"Yang J, Xu WW, Hu SJ (2015) Heart failure: advanced development in genetics and epigenetics. Biomed Res Int 2015(2):1\u201311","journal-title":"Biomed Res Int"},{"issue":"43","key":"9807_CR228","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1093\/eurheartj\/ehw450","volume":"37","author":"G Abraham","year":"2016","unstructured":"Abraham G et al (2016) Genomic prediction of coronary heart disease. Eur Heart J 37(43):3267\u20133278","journal-title":"Eur Heart J"},{"issue":"2","key":"9807_CR229","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4330\/wjc.v8.i2.211","volume":"8","author":"C Napoli","year":"2016","unstructured":"Napoli C et al (2016) Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol 8(2):211\u2013219","journal-title":"World J Cardiol"},{"issue":"22","key":"9807_CR230","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1161\/CIRCULATIONAHA.111.040071","volume":"124","author":"M Movassagh","year":"2011","unstructured":"Movassagh M et al (2011) Distinct epigenomic features in end-stage failing human hearts. Circulation 124(22):2411\u20132422","journal-title":"Circulation"},{"issue":"3","key":"9807_CR231","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/emmm.201201553","volume":"5","author":"J Haas","year":"2013","unstructured":"Haas J et al (2013) Alterations in cardiac DNA methylation in human dilated cardiomyopathy. Embo Mol Med 5(3):413\u2013429","journal-title":"Embo Mol Med"},{"issue":"16","key":"9807_CR232","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.117.027355","volume":"136","author":"B Meder","year":"2017","unstructured":"Meder B et al (2017) Epigenome-wide association study identifies cardiac gene patterning and a novel class of biomarkers for heart failure. Circulation 136(16):1528","journal-title":"Circulation"},{"key":"9807_CR233","doi-asserted-by":"crossref","unstructured":"Shu L, Arneson D, and Yang X, (2018) Bioinformatics principles for deciphering cardiovascular diseases. Encyclopedia of Cardiovascular Research and Medicine, 273\u2013292.","DOI":"10.1016\/B978-0-12-809657-4.99576-0"},{"issue":"6","key":"9807_CR234","doi-asserted-by":"publisher","first-page":"388","DOI":"10.2174\/1389202911314090006","volume":"14","author":"M Gora","year":"2013","unstructured":"Gora M, Marek K, Beata B (2013) Will global transcriptome analysis allow the detection of novel prognostic markers in coronary artery disease and heart failure? Current Genomics 14(6):388\u2013396","journal-title":"Current Genomics"},{"issue":"2","key":"9807_CR235","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ejhg.2012.129","volume":"21","author":"V Costa","year":"2013","unstructured":"Costa V et al (2013) RNA-Seq and human complex diseases: recent accomplishments and future perspectives. Eur J Hum Genet 21(2):134","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"9807_CR236","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/eurheartj\/ehu180","volume":"36","author":"S Ounzain","year":"2015","unstructured":"Ounzain S et al (2015) Fast track: editor\u2019s choice: genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. Eur Heart J 36(6):353","journal-title":"Eur Heart J"},{"issue":"5","key":"9807_CR237","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5603\/CJ.a2017.0052","volume":"24","author":"C Schiano","year":"2017","unstructured":"Schiano C et al (2017) Heart failure: pilot transcriptomic analysis of cardiac tissue by RNA-sequencing. Cardiol J 24(5):539\u2013553","journal-title":"Cardiol J"},{"issue":"3","key":"9807_CR238","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ehf2.12136","volume":"4","author":"M Toma","year":"2017","unstructured":"Toma M et al (2017) Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. Esc Heart Fail 4(3):301\u2013311","journal-title":"Esc Heart Fail"},{"key":"9807_CR239","first-page":"1","volume":"28","author":"V Rabani","year":"2017","unstructured":"Rabani V, Davani S (2017) Translational approaches in cardiovascular diseases by omics. Curr Issues Mol Biol 28:1\u201314","journal-title":"Curr Issues Mol Biol"},{"issue":"18","key":"9807_CR240","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1093\/eurheartj\/ehs162","volume":"33","author":"A Mebazaa","year":"2012","unstructured":"Mebazaa A et al (2012) Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J 33(18):2317\u20132324","journal-title":"Eur Heart J"},{"key":"9807_CR241","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.carpath.2016.10.001","volume":"26","author":"JL DeAguero","year":"2017","unstructured":"DeAguero JL et al (2017) Altered protein levels in the isolated extracellular matrix of failing human hearts with dilated cardiomyopathy. Cardiovasc Pathol 26:12\u201320","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"9807_CR242","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12967-016-0774-3","volume":"14","author":"R Raphael","year":"2016","unstructured":"Raphael R et al (2016) Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction. J Transl Med 14(1):18","journal-title":"J Transl Med"},{"issue":"1","key":"9807_CR243","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ejhf.980","volume":"20","author":"M Stenemo","year":"2018","unstructured":"Stenemo M et al (2018) Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 20(1):55\u201362","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"9807_CR244","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2006.06.063","volume":"48","author":"S Arab","year":"2006","unstructured":"Arab S et al (2006) Cardiovascular proteomics : tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 48(9):1733\u20131741","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"9807_CR245","doi-asserted-by":"publisher","first-page":"e000032","DOI":"10.1161\/HCG.0000000000000032","volume":"10","author":"S Cheng","year":"2017","unstructured":"Cheng S et al (2017) Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American Heart Association. Circ Cardiovasc Genet 10(2):e000032","journal-title":"Circ Cardiovasc Genet"},{"issue":"8","key":"9807_CR246","doi-asserted-by":"publisher","first-page":"e003190","DOI":"10.1161\/JAHA.115.003190","volume":"5","author":"WG Hunter","year":"2016","unstructured":"Hunter WG et al (2016) Metabolomic profiling identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments in clinical heart failure. J Am Heart Assoc 5(8):e003190","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"9807_CR247","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jacc.2015.10.079","volume":"67","author":"T Ahmad","year":"2016","unstructured":"Ahmad T et al (2016) Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatorysupport. J Am Coll Cardiol 67(3):291\u2013299","journal-title":"J Am Coll Cardiol"},{"key":"9807_CR248","doi-asserted-by":"publisher","unstructured":"Shu, L., et al., (2016) Mergeomics: integration of diverse genomics resources to identify pathogenic perturbations to biological systems. bioRxiv preprint; Jan. 7, 2016. https:\/\/doi.org\/10.1101\/036012","DOI":"10.1101\/036012"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09807-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-019-09807-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-019-09807-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T02:32:53Z","timestamp":1663641173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-019-09807-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":248,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["9807"],"URL":"https:\/\/doi.org\/10.1007\/s10741-019-09807-z","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"10 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The writers declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}